Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.30 |
| ▸ | SMO | Q99835 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877285 | 0.89 | MAPT (0.36) | HRH1CYP2D6ALDH1A1GAAKMT2A | |
| SCHEMBL14269777 | 0.88 | SMN1; SMN2 (0.31) | ALDH1A1GAAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4877264 | 0.88 | KCNH2 (0.37) | ALDH1A1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL4868392 | 0.87 | CBX7 (0.40) | HRH1CYP2D6ALDH1A1GAAKMT2A | |
| SCHEMBL4876431 | 0.87 | GRM5 (0.34) | ALDH1A1KMT2ASMN1; SMN2PKMGRIN2B | |
| SCHEMBL4868456 | 0.86 | ALDH1A1 (0.39) | ALDH1A1GAAKMT2ASMN1; SMN2GRIN2B | |
| SCHEMBL4876060 | 0.85 | ALDH1A1 (0.40) | ALDH1A1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4868463 | 0.84 | KMT2A (0.39) | ALDH1A1GAAKMT2ASMN1; SMN2GRIN2B | |
| SCHEMBL4877120 | 0.84 | ALDH1A1 (0.34) | ALDH1A1GAAKMT2ASMN1; SMN2GRIN2B | |
| SCHEMBL4874058 | 0.84 | ALDH1A1 (0.41) | ALDH1A1GAAKMT2ASMN1; SMN2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | HRH1 3900/4885CYP2D6 1327/4885ALDH1A1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.